Yazar "Quintela-Fandino, Miguel" için listeleme
-
Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study.
Maio, Michele; Shapira-Frommer, Ronnie; Yap, Timothy A.; Ciuleanu, Tudor; Gomez, Henry; Hill, Andrew; Lugowska, Iwona; Ozyilkan, Ozgur; Vera, Karina; Im, Seock-Ah; Kryzhanivska, Anna; Lysenko, Serhii; Schenker, Michael; Stemmer, Salomon M.; Saraf, Sanatan; Cristescu, Razvan; Jin, Fan; Gozmen, Alexander; Quintela-Fandino, Miguel (2021)